Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

We are very pleased to announce our pivotal Cohort 4 early data from the C-144-01 clinical study in advanced melanoma today, said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics.